2026 South Africa Pharma Regulatory Readiness Checklist
2 min read

South Africa continues to be a strategically important market for pharmaceutical companies looking to expand in Africa. The South African Health Products Regulatory Authority (SAHPRA) regulates drug registration, medicinal products, clinical trials, and pharmacovigilance under the Medicines and Related Substances Act (Act 101 of 1965, as amended).

With evolving regulations in 2026, pharma companies must be fully prepared to navigate registration, GMP compliance, post-marketing obligations, and Regulatory submissions.

This checklist provides an expert roadmap for Regulatory affairs teams, pharma manufacturers, and global MAHs planning entry or lifecycle management in South Africa.

1. Regulatory Authority & Legal Framework

  • SAHPRA is the national Regulatory authority overseeing the registration, evaluation, and lifecycle control of medicines and health products under the Medicines and Related Substances Act (Act 101 of 1965).
  • SAPC, established under the Pharmacy Act (Act 53 of 1974), regulates pharmacy practice, premises, and professionals; compliance with Good Pharmacy Practice (GPP) is mandatory for dispensing, storage, and distribution activities.
  • Applicable legislation and guidance include the Medicines and Related Substances Act, the Pharmacy Act, SAHPRA Regulatory Guidelines, and SAPC Rules.
  • Alignment with WHO and PIC/S GMP standards ensures internationally harmonized quality and compliance expectations.

2. Identify The Type Of Product & Registration Pathways

  • Identify correct product type: Prescription, OTC, complementary medicines, biologics, or biosimilars.
  • Select the appropriate registration pathway, including fast-track or priority pathways for essential drugs.
  • Prepare ZA-CTD formatted dossiers, with localized Module 1 data.

3. Local Responsible Person & Applicant Requirements

  • Applicant must be a juristic entity in South Africa.
  • Must designate a responsible pharmacist authorized to engage with SAHPRA.
  • The General Information guideline specifies additional requirements, including organizational charts and pharmacovigilance oversight structures; applicants should refer to the official authority website for the complete and most up-to-date requirements.

4. Dossier Preparation & Submission

  • Compile comprehensive ZA-e-CTD dossiers, including:
    • Administrative, quality (CMC), non-clinical, and clinical data.
  • Validate electronic submissions through the SAHPRA Engagement Portal.

5. GMP Compliance & Manufacturing Site Requirements

  • Ensure full GMP compliance for local and international manufacturing sites.
  • Prepare for pre-licence, routine, and risk-based inspections.
  • Maintain Site Master Files (SMF), validation protocols, and supplier qualification records.

6. Pharmacovigilance & Post-Marketing Obligations

  • Establish a robust PV system, including adverse event reporting and periodic safety updates.
  • Ensure local oversight by a Qualified Person for Pharmacovigilance (QPPV) or a responsible pharmacist.

7. Renewal & Variations

  • Registration certificates are valid for 5 years; plan renewals 6–12 months in advance.
  • Submit Type I and Type II variations for changes in manufacturing site, formulation, or labeling.

8. Import, Distribution & Licensing

  • Importers must hold SAHPRA import licenses and comply with GDP standards.
  • Ensure proper cold-chain management for biologics or temperature-sensitive products.

9. Clinical Trials Compliance

  • Obtain SAHPRA and Ethics Committee approvals before initiation.
  • Follow ICH-GCP and SA guidelines.
  • Submit electronic SAE reports promptly.

10. Fees, Timelines & Regulatory Tracking

  • Track all application, GMP, and renewal fees.
  • Monitor submission timelines, queries, and approval status via the Engagement Portal.
  • Maintain a Regulatory intelligence system for ongoing updates.

11. Strategic Considerations for 2026

  • Monitor SAHPRA’s alignment with ICH guidelines and international harmonization.
  • Prepare for digital submissions, e-labeling, and electronic safety reporting.
  • Evaluate regional African harmonization opportunities for joint filings.

12. Expert Recommendations

  • Engage local Regulatory consultants for guidance on complex pathways.
  • Conduct internal audits on dossiers, GMP compliance, and PV systems.
  • Develop contingency plans for potential Regulatory delays or additional data requests.

Bottom Line:
Proactive preparation, technical dossier compliance, robust pharmacovigilance systems, and alignment with GMP and ICH standards are essential for successful market entry and lifecycle management in South Africa in 2026.

For expert support in drug registration, GMP compliance, and Regulatory strategy in South Africa, connect with our Regulatory Affairs specialists today.

Subscribe to Freyr Blog